Does adding neoadjuvant check‐point inhibitor in high risk locally advanced rectal cancer increase tumour response?

2021 ◽  
Vol 91 (11) ◽  
pp. 2253-2254
Author(s):  
Joseph C. Kong ◽  
Peadar Waters ◽  
Satish K. Warrier ◽  
Alexander G. Heriot
Keyword(s):  
Rectal Cancer ◽  
High Risk ◽  
Locally Advanced ◽  
Tumour Response ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Check Point

scholarly journals OC-0510 MRI radiomics to predict tumour response in patients with locally advanced rectal cancer

2019 ◽  
Vol 133 ◽  
pp. S265-S266
Author(s):  
P. Bulens ◽  
A. Couwenberg ◽  
M. Intven ◽  
A. Debucquoy ◽  
V. Vandecaveye ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Locally Advanced ◽  
Tumour Response ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

Predictive value of 18FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy

2013 ◽  
Vol 28 (9) ◽  
pp. 1217-1224 ◽  
Author(s):  
Jong Wan Kim ◽  
Hyun Chul Kim ◽  
Ji Won Park ◽  
Sung Chan Park ◽  
Dae Kyung Sohn ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Predictive Value ◽  
Locally Advanced ◽  
Tumour Response ◽  
Advanced Rectal Cancer ◽  
Preoperative Chemoradiotherapy ◽  
Locally Advanced Rectal Cancer ◽  
18Fdg Pet ◽  
Pet Ct

scholarly journals The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer

2010 ◽  
Vol 5 (1) ◽  
Author(s):  
Pablo Palma ◽  
Raquel Conde-Muíño ◽  
Antonio Rodríguez-Fernández ◽  
Inmaculada Segura-Jiménez ◽  
Rocío Sánchez-Sánchez ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Locally Advanced ◽  
Tumour Response ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Metabolic Imaging

Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?

2000 ◽  
Vol 56 (2) ◽  
pp. 239-244 ◽  
Author(s):  
Hany Elsaleh ◽  
Peter Robbins ◽  
David Joseph ◽  
Brenda Powell ◽  
Fabianne Grieu ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Locally Advanced ◽  
Tumour Response ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

scholarly journals Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial

Oncotarget ◽  
2015 ◽  
Vol 6 (30) ◽  
pp. 30394-30407 ◽  
Author(s):  
Antonio Avallone ◽  
Biagio Pecori ◽  
Franco Bianco ◽  
Luigi Aloj ◽  
Fabiana Tatangelo ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
High Risk ◽  
Critical Role ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer

Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before surgery in patients with locally advanced rectal cancer (A phase II study)

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Mai Ezzat Elhawi ◽  
Aly Mohammed Azmy ◽  
Ramy Refaat Youssef Ghali ◽  
Ass. Prof. Dr. Nagy Samy Gobran ◽  
Ass. Prof. Dr. Marwa Mosaad Shakweer ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
High Risk ◽  
Induction Chemotherapy ◽  
Locally Advanced ◽  
Complete Response ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Pathological Response ◽  
Toxicity Profile ◽  
Complete Pathological Response

Abstract Background Locally advanced rectal cancer (LARC) has a high incidence of local and distant relapse even after adequate treatment. The emerging role of neoadjuvant induction chemotherapy may allow initial down staging of the primary tumor, less toxicity profile and early treatment of micrometastatic disease followed by chemoradiation, and optimum local control may be attained, with the hope of increased complete response rates Objectives to identify the effect of induction chemotherapy with oxaliplatin and capecitabine (CapeOx) before concurrent chemoradiation in locally advanced rectal cancer in terms of response and toxicity. Primary end point is assessment of complete pathological response rate. Patient and Methods patients with MRI based criteria of high-risk LARC (T4 tumors, tumors within 2 mm of mesorectal fascia, T3 tumors at or below levators and T2-4N+ve tumors) were included. Patients received 12 weeks of induction capecitabine/oxaliplatin followed by concomitant capecitabine and conventional three dimensional conformal radiotherapy. Surgery was done at least 6 weeks after CCRTH. Results Thirty five patients with LARC were recruited during the period from December 2017 till January 2019. Five patients (20.8%) had a pathological complete response (TRG 0) (ypT0N0). Another three patients (12.5%) had near complete pathological response (TRG 1). While unfortunately 29.2% and 37.5% had partial response and poor response respectively. Conclusion Induction chemotherapy could be a promising option for better response rates either clinical or pathological for high risk LARC patients with acceptable toxicity profile.

Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?

2018 ◽  
Vol 89 ◽  
pp. 1-8 ◽  
Author(s):  
Marloes Swets ◽  
Peter J.K. Kuppen ◽  
Erik J. Blok ◽  
Hans Gelderblom ◽  
Cornelis J.H. van de Velde ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Selection Tool

scholarly journals BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer

2017 ◽  
Vol 28 ◽  
pp. iii126 ◽  
Author(s):  
Rob Glynne-Jones ◽  
Marcia Hall ◽  
Sarah Pearce ◽  
Sam Bosompem ◽  
John Bridgewater ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
High Risk ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Randomised Study
Sign in / Sign up

Export Citation Format

Share Document